UNASSIGNED: @entity1092 administration during gestational period causes behavior and biochemical deficits similar to those observed in @entity1 with @entity72 . Although worldwide prevalence of @entity72 has been increased continuously, therapeutic agents to ameliorate the social impairment are very limited. The present study has been structured to investigate the therapeutic potential of @entity2493 receptor agonist, @entity29050 in prenatal @entity1092 (Pre-VPA) induced @entity72 in animals. Pre- @entity3262 has produced reduction in social interaction (three chamber social behavior apparatus), spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, @entity750 levels (prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complex I, II, IV). Furthermore, Pre- @entity3262 has increased locomotor activity (actophotometer), @entity148 , brain oxidative stress ( @entity4466 reactive species, @entity2041 , and catalase), nitrosative stress ( @entity3542 / @entity1507 ), @entity32 (brain and ileum @entity3335 activity), @entity460 levels and blood brain barrier leakage in animals. Treatment with @entity29050 has significantly attenuated Pre- @entity3262 induced reduction in social interaction, spontaneous alteration, exploratory activity intestinal motility, @entity750 levels and prefrontal cortex mitochondrial complex activity. Furthermore, @entity29050 also attenuated Pre- @entity3262 induced increase in locomotion, @entity148 , brain oxidative stress, nitrosative stress, @entity32 , @entity460 levels and blood brain barrier leakage. It is concluded that, Pre-VPA has induced @entity72 , which was attenuated by @entity29050 . @entity29050 has shown ameliorative effect on behavioral, neurochemical and blood brain barrier alteration in Pre- @entity3262 exposed animals. Thus @entity2493 receptor agonists may provide beneficial therapeutic strategy for managing @entity72 .

Benefits of XXXX in behavioral, neurochemical and blood brain barrier alterations in prenatal @entity1092 induced @entity72 .

@entity1 :: ('9606', 'Species') :: ['humans'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity3335 :: ('4353', 'Gene') :: ['myeloperoxidase'] @entity3262 :: ('D014635', 'Chemical') :: ['VPA'] @entity1092 :: ('MESH:D014635', 'Chemical') :: ['Valproic acid', 'valproic acid'] @entity3542 :: ('CHEBI:16301', 'Chemical') :: ['nitrite'] @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione'] @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate'] @entity2493 :: ('MESH:D008550', 'Chemical') :: ['melatonin'] @entity29050 :: ('MESH:C084711', 'Chemical') :: ['agomelatine', 'Agomelatine'] @entity72 :: ('MESH:D002659', 'Disease') :: ['autism spectrum disorder'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety'] @entity4466 :: ('MESH:C029684', 'Chemical') :: ['thiobarbituric acid'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']
@entity29050 :: (MESH:C084711,Chemical) :: ['agomelatine']
